Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Profit After Tax (2018 - 2025)

BioNexus Gene Lab's Profit After Tax history spans 8 years, with the latest figure at -$708991.0 for Q3 2025.

  • For Q3 2025, Profit After Tax rose 47.3% year-over-year to -$708991.0; the TTM value through Sep 2025 reached -$2.3 million, down 143.94%, while the annual FY2024 figure was -$1.6 million, 39.2% up from the prior year.
  • Profit After Tax for Q3 2025 was -$708991.0 at BioNexus Gene Lab, down from -$616172.0 in the prior quarter.
  • Across five years, Profit After Tax topped out at $338744.0 in Q1 2021 and bottomed at -$2.6 million in Q3 2023.
  • The 5-year median for Profit After Tax is -$103757.0 (2024), against an average of -$304224.7.
  • The largest annual shift saw Profit After Tax surged 591.92% in 2021 before it crashed 3271.0% in 2023.
  • A 5-year view of Profit After Tax shows it stood at $89243.0 in 2021, then crashed by 275.89% to -$156969.0 in 2022, then soared by 296.51% to $308463.0 in 2023, then tumbled by 212.92% to -$348319.0 in 2024, then tumbled by 103.55% to -$708991.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Profit After Tax are -$708991.0 (Q3 2025), -$616172.0 (Q2 2025), and -$623327.0 (Q1 2025).